WST Research Note — Growth Meets a Credibility Test
West Pharmaceutical’s strong quarter meets a harder test from valuation, market structure and unresolved oral-drug substitution risk.
WST
WST Deep Coverage Review — Analysis as of July 27, 2026
West Pharmaceutical’s beat-and-raise supports the recovery thesis, but a heavy-volume reversal and oral-drug substitution risk keep confirmation incomplete.